Investment announcements in the global healthtech industry continue to arrive, yet headlines about collapsing valuations and cost-cutting swirl through the same news cycle. Taken together, these signals paint a nuanced picture rather than a tale of boom or bust.
A close look at the facts now in front of us shows a sector growing more selective rather than uniformly bullish or bleak.
Consider the past few weeks. They illustrate that capital has not disappeared. Leeds-based Envoke secured €1.1 million to refine software that lets laboratory staff practise on virtual instruments, cutting training time and machine downtime.
In Mumbai, WhiteHat Jr founder Karan Bajaj resurfaced with Complement 1 and $16 million of seed capital led by Owl Ventures and Blume Ventures. The platform supplies daily coaching on nutrition, movement and stress management for cancer patients and people at high risk of the disease. Company data claims 37% fewer treatment side effects, 18% less pain and 27% better sleep, with adherence above 90%.
Saudi Arabia’s Kilow raised $2.5 million from Sanabil Venture Studio and Stryber. Launched last year by Fahed Al Essa, the service pairs at-home lab tests with real-time tracking and medical advice for weight management.
Bigger cheques have also landed. Los Angeles-based Akido drew $60 million in Series B funding led by Oak HC FT with support from Greco, SNR, Y Combinator and others. In India, PB Healthcare Services collected $218 million at a post-money valuation of $243 million. The plan is to build a 1,000-bed hospital network in the National Capital Region and accelerate product development.
Taken individually, these start-ups tackle different points of the care continuum, but collectively they show where investor appetite is shifting: toward tangible productivity gains and demonstrable patient outcomes.
Early Stage Cheques Still Arrive
These deals coexist with a funding landscape that is volatile and uneven. Government data show more than 10,000 recognised health and life-science startups in India last year, a compound annual growth rate of 127% since 2016. EY projects that telemedicine will grow 31% a year and e-pharmacy 44% through 2025, taking the wider healthtech market toward $50 billion by 2033.
Yet capital flows have swung sharply.
Healthtech startups in India attracted $984 million in 2021 and $966 million in 2022, only to plunge to $419 million in 2023. Last year brought a rebound to $1.13 billion across 112 disclosed deals, with growth and late-stage rounds contributing almost 80% of the total.
PharmEasy led with $216 million, while Engrail and NephroPlus drew $157 million and $102 million. PharmEasy’s valuation still slipped from ₹47,000 crore to ₹3,800 crore, a reminder that price discipline has tightened across the board.
The sharp swings in funding totals reflect a flight to quality rather than a wholesale retreat. Tighter valuations, then, are the mirror image of investor discipline, not a rejection of the sector itself.
Systemic Pressures Cloud the Outlook
Zooming out, global forces complicate the picture. A World Economic Forum briefing warns that progress in life expectancy and reductions in maternal and child mortality are slowing. Climate shocks, an ageing population, rising non-communicable disease and persisting inequalities already stretch national budgets.
Added to these is geopolitical disruption: lower development assistance from Europe and the United States, new trade barriers that disturb medical supply chains and a weakening of multilateral health programmes.
Human Rights Watch, using World Health Organisation (WHO) data, found that 141 governments spent less than 5% of their gross domestic product on public health in 2022. That threshold is widely regarded as a minimum for universal health coverage. 84% of the world’s population lives in those countries. At least 48 lower-income governments paid more to foreign creditors than to healthcare, limiting room for investment in clinics, staff and prevention.
Domestic policy choices add further uncertainty. In the United States, Health Secretary Robert F Kennedy Jr has defended cuts that would reduce National Institutes of Health funding by 40% while laboratories face the nation’s worst measles outbreak since 2000.
A bill before Congress would extend tax cuts by trimming federal healthcare subsidies, a move the Congressional Budget Office says could leave 13.7 million Americans uninsured. Research budgets, workforce pipelines and vaccination uptake all hang in the balance.
Against that backdrop, innovators and investors are pursuing models that promise measurable savings or capacity gains. Envoke targets avoidable downtime in diagnostics, Complement 1 focuses on adherence to lifestyle changes that lower side effects and costs, Kilow combines remote testing with personalised advice, Akido applies artificial intelligence to administrative bottlenecks and PB Healthcare is building physical infrastructure at scale. Each seeks to turn system pressure into a commercial opportunity.
The message for founders is pragmatic. Capital has not vanished, but it favours propositions that address workforce shortages, chronic disease management or operational waste with verifiable outcomes. For policymakers, the evidence underscores that public funding remains the keystone.
Where tax capacity is low and debt service high, external finance and new instruments will be essential, yet donor grants alone cannot carry the weight. The sector is moving toward a cautious equilibrium: fewer broad promises, closer scrutiny of unit economics and impact, and a search for financial structures that align private returns with public resilience.
In short, healthtech is neither in free fall nor in a new bubble. It is travelling a narrower path where disciplined investors back tools that reduce expensive problems while governments wrestle with the basic question of who pays and how much. Progress will depend on blending scarce public resources with targeted private capital and on evidence that technology can deliver more with the funds that remain on the table.
Edited by Harshajit Sarmah
